163 related articles for article (PubMed ID: 18841052)
21. Emerging strategies to treat chronic immune thrombocytopenic purpura.
Newland A
Eur J Haematol Suppl; 2008 Feb; (69):27-33. PubMed ID: 18211570
[TBL] [Abstract][Full Text] [Related]
22. AMG 531: an investigational thrombopoiesis-stimulating peptibody.
Nichol JL
Pediatr Blood Cancer; 2006 Oct; 47(5 Suppl):723-5. PubMed ID: 16933266
[TBL] [Abstract][Full Text] [Related]
23. The role of AMG-531 in the treatment of thrombocytopenia in idiopathic thrombocytopenic purpura and myelodysplastic syndromes.
Tiu RV; Sekeres MA
Expert Opin Biol Ther; 2008 Jul; 8(7):1021-30. PubMed ID: 18549331
[TBL] [Abstract][Full Text] [Related]
24. Chronic immune thrombocytopenic purpura. New agents.
Rodeghiero F; Ruggeri M
Hamostaseologie; 2009 Jan; 29(1):76-9. PubMed ID: 19151853
[TBL] [Abstract][Full Text] [Related]
25. Systematic literature review and meta-analysis on use of Thrombopoietic agents for chemotherapy-induced thrombocytopenia.
Soff GA; Ray-Coquard I; Rivera LJM; Fryzek J; Mullins M; Bylsma LC; Park JK
PLoS One; 2022; 17(6):e0257673. PubMed ID: 35679540
[TBL] [Abstract][Full Text] [Related]
26. Platelet production bolstered with romiplostim approval.
Morrow T
Manag Care; 2008 Oct; 17(10):49-50. PubMed ID: 18990926
[No Abstract] [Full Text] [Related]
27. Eltrombopag in patients with chronic liver disease.
Giannini EG; Afdhal NH
Expert Opin Pharmacother; 2013 Apr; 14(5):669-78. PubMed ID: 23452139
[TBL] [Abstract][Full Text] [Related]
28. Romiplostim: a novel thrombopoiesis-stimulating agent.
Perreault S; Burzynski J
Am J Health Syst Pharm; 2009 May; 66(9):817-24. PubMed ID: 19386944
[TBL] [Abstract][Full Text] [Related]
29. Immune thrombocytopenic purpura--from agony to agonist.
Schwartz RS
N Engl J Med; 2007 Nov; 357(22):2299-301. PubMed ID: 18046034
[No Abstract] [Full Text] [Related]
30. New therapeutic options for adult chronic immune thrombocytopenic purpura: a brief review.
Panzer S
Vox Sang; 2008 Jan; 94(1):1-5. PubMed ID: 17973895
[TBL] [Abstract][Full Text] [Related]
31. Romiplostim: a second-generation thrombopoietin agonist.
Cohn CS; Bussel JB
Drugs Today (Barc); 2009 Mar; 45(3):175-88. PubMed ID: 19436840
[TBL] [Abstract][Full Text] [Related]
32. Thrombopoietin mimetic agents in the management of immune thrombocytopenic purpura.
Newland A
Semin Hematol; 2007 Oct; 44(4 Suppl 5):S35-45. PubMed ID: 18096471
[TBL] [Abstract][Full Text] [Related]
33. Orphan disease gains second treatment option.
Morrow T
Manag Care; 2009 Jan; 18(1):47-9. PubMed ID: 19186672
[No Abstract] [Full Text] [Related]
34. Thrombocytopenia in MDS: epidemiology, mechanisms, clinical consequences and novel therapeutic strategies.
Li W; Morrone K; Kambhampati S; Will B; Steidl U; Verma A
Leukemia; 2016 Mar; 30(3):536-44. PubMed ID: 26500138
[TBL] [Abstract][Full Text] [Related]
35. [Recent advances in the treatment of idiopathic thrombocytopenic purpura].
Kurata Y
Rinsho Ketsueki; 2007 May; 48(5):355-62. PubMed ID: 17571579
[No Abstract] [Full Text] [Related]
36. Thrombopoietic agents in immune thrombocytopenia.
Ghanima W; Bussel JB
Semin Hematol; 2010 Jul; 47(3):258-65. PubMed ID: 20620437
[TBL] [Abstract][Full Text] [Related]
37. Clinical findings with the first generation of thrombopoietic agents.
Vadhan-Raj S
Semin Hematol; 2010 Jul; 47(3):249-57. PubMed ID: 20620436
[TBL] [Abstract][Full Text] [Related]
38. Biologic aspects of thrombopoietins and the development of therapeutic agents.
Solberg LA
Curr Hematol Rep; 2005 Nov; 4(6):423-8. PubMed ID: 16232377
[TBL] [Abstract][Full Text] [Related]
39. New thrombopoietic agents: introduction.
Bussel JB; Kuter DJ
Semin Hematol; 2010 Jul; 47(3):211. PubMed ID: 20620430
[No Abstract] [Full Text] [Related]
40. FDA approves thrombopoiesis-stimulating agent.
Thompson CA
Am J Health Syst Pharm; 2008 Oct; 65(19):1788. PubMed ID: 18796411
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
